Relmada Therapeutics is a clinical-stage biotechnology company developing innovative treatments for high-unmet-need indications, with no approved products or commercial revenue. The company's lead candidate, NDV-01, is a controlled-release intravesical formulation combining gemcitabine and docetaxel for non-muscle-invasive bladder cancer, designed to deliver therapy in under five minutes rather than requiring multi-hour infusions; a second program, Sepranolone, is a novel neurosteroid targeting neurological disorders including Prader-Willi syndrome and Tourette syndrome. Relmada funds clinical development through capital investment and operates with a lean structure, intending to pursue FDA approval pathways and establish manufacturing and commercial infrastructure upon regulatory clearance.